EICHORCondition: Schizophrenia or Schizoaffective · Sponsor: Intra-Cellular Therapies, Inc.
Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Collaborative Neuroscience Research, LLC | Los Alamitos, California, United States | — |
| CenExeli Research LLC | Atlanta, Georgia, United States | — |
| Atlanta Center for Medical Research | Atlanta, Georgia, United States | — |
| Hassman Research Institute, LLC. | Marlton, New Jersey, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06627413